Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Comp

SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Comp

Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-t

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) wit

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Ne

Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the a

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared t

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERI

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Com

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics

Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CAT

ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CA

 The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed comp

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-m

Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contrib

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor

Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Compa

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirm

The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the a

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharm

HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an

UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the pr

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio

RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperf

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the

Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with